Inactive Instrument
Five Prime Therapeutics, Inc. Stock
Stocks
FPRX
US33830X1046
Biotechnology & Medical Research
| 1 day | +0.03% |
| Manager | Title | Age | Since |
|---|---|---|---|
James Bradner
CEO | Chief Executive Officer | 53 | - |
Peter Griffith
DFI | Director of Finance/CFO | 67 | - |
Jonathan Graham
LAW | General Counsel | 65 | - |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 16/04/21 | Issuer sale | Chief Executive Officer | 548,971 | 1.1788% | ||
| 16/04/21 | Issuer sale | Director | 46,250 | 0.0993% | ||
| 16/04/21 | Issuer sale | Director | 60,000 | 0.1288% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.03% | +0.16% | - | - | 1.74B | |
| +0.68% | +5.92% | +77.86% | +139.22% | 59.1B | |
| +2.32% | +5.03% | +75.26% | +91.40% | 55.19B | |
| +3.86% | +6.93% | -11.32% | -9.53% | 24.67B | |
| +4.30% | +7.95% | +14.11% | +437.83% | 24.19B | |
| +4.74% | +13.68% | +43.36% | -4.67% | 19.69B | |
| -0.29% | +9.78% | +43.90% | -28.41% | 17.56B | |
| 0.00% | +20.78% | +186.15% | +361.42% | 16.22B | |
| +6.72% | +19.38% | +37.85% | - | 14.84B | |
| +3.50% | +1.97% | +21.02% | +191.95% | 14.04B | |
| Average | +2.59% | +8.57% | +54.24% | +147.40% | 27.28B | |
| Weighted average by Cap. | +2.45% | +6.47% | +58.32% | +136.98% |
Employees
51
